HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY AS A SIDE-EFFECT OF DEXAMETHASONE TREATMENT FOR BRONCHOPULMONARY DYSPLASIA

被引：30

作者：

BRAND, PLP

VANLINGEN, RA

BRUS, F

TALSMA, MD

ELZENGA, NJ

机构：

[1] UNIV GRONINGEN HOSP,BEATRIX CHILDRENS CLIN,DIV NEONATOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS

[2] UNIV GRONINGEN HOSP,BEATRIX CHILDRENS CLIN,DIV PEDIAT CARDIOL,9713 EZ GRONINGEN,NETHERLANDS

来源：

ACTA PAEDIATRICA | 1993年 / 82卷 / 6-7期

关键词：

BRONCHOPULMONARY DYSPLASIA; DEXAMETHASONE; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY;

D O I：

10.1111/j.1651-2227.1993.tb12771.x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

We report three infants who developed hypertrophic obstructive cardiomyopathy during dexamethasone treatment for bronchopulmonary dysplasia. In all three infants, echocardiography had ruled out cardiac abnormalities prior to the dexamethasone course. The hypertrophic obstructive cardiomyopathy appeared and progressed during dexamethasone therapy and resolved completely after its cessation. This suggests a causative association between the hypertrophic obstructive cardiomyopathy and the exogenous glucocorticosteroid therapy. The mechanism of this dexamethasone-related hypertrophic obstructive cardiomyopathy is unclear. This complication may be encountered more frequently with the increasing use of dexamethasone in infants with bronchopulmonary dysplasia.

引用

页码：614 / 617

页数：4

共 21 条

[11]

MARON BJ, 1989, HEART DISEASE INFANT, P940

[12]

MELNICK G, 1980, PEDIATRICS, V66, P589

[13] ANTI-INFLAMMATORY STEROIDS REDUCE TISSUE PG SYNTHETASE-ACTIVITY AND ENHANCE PG BREAKDOWN [J].